☆ 4.8 Review

Evaluation of the safety profile of COVID-19 vaccines: a rapid review

BMC MEDICINE (2021)

Related references

Note: Only part of the references are listed.

Article Infectious Diseases

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

Shengli Xia et al.

Summary: The inactivated SARS-CoV-2 vaccine, BBIBP-CorV, demonstrated safety and immunogenicity in two age groups. Humoral responses against SARS-CoV-2 were induced in all vaccine recipients by day 42. A two-dose immunisation with 4 mu g vaccine on days 0 and 21 or days 0 and 28 achieved higher neutralising antibody titres compared to other dosing schedules.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine

Tom Shimabukuro et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Jordan R. Barrett et al.

Summary: The study demonstrates that a booster dose of ChAdOx1 nCoV-19 is safer and better tolerated than priming doses. The booster dose significantly enhances anti-spike neutralizing antibody titers and other functional antibody responses. These data support the two-dose vaccine regime currently being evaluated in phase 3 clinical trials.

NATURE MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

J. Sadoff et al.

Summary: The study conducted a multicenter, placebo-controlled, phase 1-2a trial, with participants randomly assigned to receive the Ad26.COV2.S vaccine. The results showed that the safety and immunogenicity profiles of the vaccine support further development.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Reprint Surgery

Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine - United States, December 21, 2020-January 10, 2021 (Reprinted from AJT, vol 70, pg 125-129, 2021)

Tom Shimabukuro

AMERICAN JOURNAL OF TRANSPLANTATION (2021)

Add to Collection

Article Medicine, General & Internal

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Merryn Voysey et al.

Summary: The AZD1222 vaccine has been approved for emergency use in the UK with an interval of 4-12 weeks between doses. Analysis shows that the vaccine is efficacious with two doses and provides immunoprotection after the first dose before the second dose is administered.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Denis Y. Logunov et al.

Summary: The Gam-COVID-Vac vaccine showed 91.6% efficacy against COVID-19 in the phase 3 trial, with good safety and tolerability in a large cohort of participants.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial

Peter Richmond et al.

Summary: A study in Australia evaluated the dose-finding and adjuvant justification of the SCB-2019 vaccine against SARS-CoV-2. The vaccine, which contains a stabilised trimeric form of the spike protein (S-Trimer) combined with AS03 or CpG/Alum adjuvants, elicited robust humoral and cellular immune responses in both younger and older adults.

LANCET (2021)

Add to Collection

Article Infectious Diseases

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Zhiwei Wu et al.

Summary: The study showed that CoronaVac vaccine is safe and well tolerated in older adults, and is able to induce neutralizing antibody levels. The highest dose of 3 μg of the vaccine can generate neutralizing antibody levels similar to the 6 μg dose, supporting the use of the 3 μg dose CoronaVac in phase 3 trials.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Infectious Diseases

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Yanjun Zhang et al.

Summary: This study investigated the safety, tolerability, and immunogenicity of the COVID-19 vaccine candidate CoronaVac, and found that the 3 μg dose showed higher seroconversion rates in the phase 2 trial.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Infectious Diseases

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

Raches Ella et al.

Summary: BBV152 vaccine, consisting of whole-virion inactivated SARS-CoV-2 with Algel and IMDG, showed high neutralizing antibody responses in phase 1 trial and better reactogenicity in phase 2 trial. The 6 mu g with Algel-IMDG formulation has been chosen for phase 3 efficacy trial.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Editorial Material Infectious Diseases

Concerns and motivations about COVID-19 vaccination

Rachael H. Dodd et al.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Medicine, General & Internal

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Noa Dagan et al.

Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Immunology

Safety of the First Dose of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients

Brian J. Boyarsky et al.

TRANSPLANTATION (2021)

Add to Collection

Article Immunology

A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine

Laurence Chu et al.

Summary: The study evaluated the safety and immunogenicity of the mRNA-1273 vaccine in healthy adults, showing significant immune responses to SARS-CoV-2 with acceptable safety profile. This vaccine induced higher antibody levels at a 100 mg dose, confirming its immunogenicity and safety for use in a 2-dose regimen.

VACCINE (2021)

Add to Collection

Article Public, Environmental & Occupational Health

First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021

Julianne Gee et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Editorial Material Immunology

Immediate Reactions After the First Dose of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Messenger RNA Vaccines Do Not Preclude Second-Dose Administration

Kristine Vanijcharoenkarn et al.

Summary: Addressing immediate adverse events after the first dose of COVID-19 vaccines, especially allergic reactions, is crucial for effective diagnosis and management to combat the pandemic.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [18F]FDG PET-CT and relevance to study interpretation

Dan Cohen et al.

Summary: The study investigated the incidence of VAHL after BNT162b2 vaccination and its relevance to PET-CT interpretation in oncologic patients. VAHL was found to be more common and with higher intensity following the booster dose of the vaccine. It is recommended to schedule PET-CT scans during time intervals with lower incidence of VAHL to avoid false or equivocal reports in oncology patients.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

Add to Collection

Article Immunology

Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China

Mei-Xian Zhang et al.

Summary: The study aimed to assess the safety of the CoronaVac vaccine among healthcare workers, finding a low incidence of adverse reactions with localized pain at the injection site being the most common, indicating an acceptable safety profile for the vaccine among this population.

EXPERT REVIEW OF VACCINES (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines

Johanna Chapin-Bardales et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Medicine, General & Internal

US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021

Isaac See et al.

Summary: Cases of CVST with thrombocytopenia following Ad26.COV2.S vaccination have been reported in the US, leading to serious outcomes. This case series may provide guidance for clinical management and further investigation into the potential relationship between Ad26.COV2.S vaccine and CVST with thrombocytopenia.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Infectious Diseases

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials

Shilong Yang et al.

Summary: The results from Phase 1 and Phase 2 trials of the COVID-19 vaccine ZF2001 show that the vaccine is well tolerated and immunogenic, supporting the use of a 25 microgram dose in a three-dose schedule for large-scale evaluation in a Phase 3 trial.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Infectious Diseases

Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study

Cristina Menni et al.

Summary: This study investigated the safety and effectiveness of the BNT162b2 and ChAdOx1 nCoV-19 vaccines in a UK community setting. The results showed that the frequencies of side effects from these vaccines were lower than reported in clinical trials, and a significant reduction in the risk of SARS-CoV-2 infection was observed starting at 12 days after vaccination.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Medicine, General & Internal

Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons

Tom T. Shimabukuro et al.

Summary: Preliminary data indicates that there are no obvious safety signals among pregnant women who received mRNA Covid-19 vaccines, but more data is needed for further confirmation. Adverse reactions such as injection-site pain were reported more frequently in pregnant women, but most pregnancies resulted in live births with some cases of preterm birth and small size for gestational age.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center

William Daniel et al.

Summary: Following the rollout of mRNA SARS-CoV-2 vaccines under emergency use authorization, there was a significant decrease in the incidence of SARS-CoV-2 infections among health care workers at the University of Texas Southwestern Medical Center.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Nina H. Schultz et al.

Summary: This study reports five cases of venous thrombosis and thrombocytopenia occurring 7 to 10 days after receiving the ChAdOx1 nCoV-19 vaccine, suggesting a rare vaccine-induced immune thrombotic thrombocytopenia. The condition, which can lead to catastrophic outcomes such as cerebral venous sinus thrombosis, may be treated with intravenous immune globulin.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Andreas Greinacher et al.

Summary: After vaccination with ChAdOx1 nCov-19, rare immune thrombotic thrombocytopenia can occur due to platelet-activating antibodies against PF4, resulting in various thrombotic events. Most patients in this case series were women, with fatal outcomes such as cerebral venous thrombosis and intracranial hemorrhage. Additional studies are needed to further investigate and understand this phenomenon.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

S. A. Madhi et al.

Summary: The ChAdOx1 nCoV-19 vaccine did not provide significant protection against mild-to-moderate Covid-19 caused by the B.1.351 variant, with an efficacy of 10.4%. The incidence of serious adverse events was balanced between the vaccine and placebo groups.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination - Response from the Manufacturer

Jerald Sadoff et al.

Summary: The manufacturer responds to recent reports of thrombosis and severe thrombocytopenia in recipients of the Ad26.COV2.S vaccine.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Pharmacology & Pharmacy

Atypical thrombosis associated with VaxZevria® (AstraZeneca) vaccine: Data from the French Network of Regional Pharmacovigilance Centres

Valerie Gras-Champel et al.

THERAPIE (2021)

Add to Collection

Article Immunology

The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18?59 years: A phase I randomized, double-blinded, controlled trial

Jing Pu et al.

Summary: The study demonstrated that the inactivated SARS-CoV-2 vaccine was safe and immunogenic in individuals aged 18-59. Seroconversion rates and antibody titers indicated a robust immune response induced by the vaccine. Transcriptome analysis revealed the genetic diversity of immune responses triggered by the vaccine.

VACCINE (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Thrombosis after covid-19 vaccination These rare events must not derail vaccination efforts

Paul R. Hunter

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Medicine, General & Internal

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study

Anton Pottegard et al.

Summary: This study assessed rates of cardiovascular and haemostatic events in Denmark and Norway after vaccination with the Oxford-AstraZeneca vaccine ChAdOx1-S, finding increased rates of venous thromboembolic events among recipients. Despite slightly higher rates of thrombocytopenia/coagulation disorders and bleeding, the overall safety outcomes were largely reassuring.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Biotechnology & Applied Microbiology

Safety survey by clinical pharmacists on COVID-19 vaccination from a single center in China

Guangfei Wang et al.

Summary: This study highlighted the important role and value of clinical pharmacists in the implementation of COVID-19 vaccination through investigating and analyzing the safety of COVID-19 vaccination in 2305 individuals. The common adverse reactions during vaccination were mostly mild and tolerable, indicating good safety of the inactivated COVID-19 vaccine.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2021)

Add to Collection

Letter Medicine, General & Internal

Association of Facial Paralysis With mRNA COVID-19 Vaccines A Disproportionality Analysis Using the World Health Organization Pharmacovigilance Database

Lucie Renoud et al.

Summary: This analysis uses the WHO pharmacovigilance database to investigate the potential safety signal of facial paralysis following COVID-19 vaccination.

JAMA INTERNAL MEDICINE (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine — United States, March–April 2021

David K. Shay et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Letter Cardiac & Cardiovascular Systems

Incidence of cerebral venous thrombosis and COVID-19 vaccination: possible causal effect or just chance?

Giovanni de Simone et al.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2021)

Add to Collection

Review Chemistry, Medicinal

COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials

Zhi-Peng Yan et al.

Summary: Various strategies, including vaccine development, have been designed to contain the COVID-19 pandemic. This study reviews the most recent data of 12 vaccines to evaluate their efficacy, safety profile, and usage in various populations, highlighting the importance of comparing protective efficacy and risks of vaccination for global control through herd immunity.

PHARMACEUTICALS (2021)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

Cerebral Venous Sinus Thrombosis in the US Population, After Adenovirus-Based SARS-CoV-2 Vaccination, and After COVID-19

Behnood Bikdeli et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland

C. R. Simpson et al.

Summary: Analysis of data from the EAVE II cohort in Scotland has shown that a first dose of the ChAdOx1 nCoV-19 vaccine may be associated with increased risks of idiopathic thrombocytopenic purpura, arterial thromboembolic events, and hemorrhagic events. However, there were no positive associations found between the BNT162b2 vaccine and these adverse events.

NATURE MEDICINE (2021)

Add to Collection

Article Immunology

Adverse events following mRNA SARS-CoV-2 vaccination among US nursing home residents

Barbara H. Bardenheier et al.

Summary: This study found no significant adverse events associated with COVID-19 vaccination among nursing home residents, including neurologic outcomes, anaphylaxis, or cardiac events. The safety of receiving the first or second dose of the vaccine in this population from December 18, 2020 to March 7, 2021 was confirmed.

VACCINE (2021)

Add to Collection

Article Biotechnology & Applied Microbiology

Preliminary evidence on the safety profile of BNT162b2 (Comirnaty): new insights from data analysis in EudraVigilance and adverse reaction reports from an Italian health facility

Michele Gringeri et al.

Summary: The first available vaccine against SARS-CoV-2 in Italy is the two-dose mRNA-based vaccine BNT162b2 developed by Pfizer-BioNTech. Over 2000 healthcare professionals at the Fatebenefratelli-Sacco hospital have received both doses. By analyzing spontaneous safety reports and comparing them to those submitted in EudraVigilance and clinical trials, several new and unexpected adverse reactions have been identified, which will be useful for reviewing the safety profile of this vaccine.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2021)

Add to Collection

Letter Otorhinolaryngology

Preliminary Analysis of Association Between COVID-19 Vaccination and Sudden Hearing Loss Using US Centers for Disease Control and Prevention Vaccine Adverse Events Reporting System Data

Eric J. Formeister et al.

JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY (2021)

Add to Collection

Article Immunology

COVID-19 mRNA Vaccines Are Generally Safe in the Short Term: A Vaccine Vigilance Real-World Study Says

Gang Chen et al.

Summary: Prophylactic vaccination of COVID-19 mRNA vaccines is the first large-scale application of its kind in humans. Adverse events following immunization (AEFIs) were mostly non-severe local or systemic reactions. Allergy history may be a risk factor for anaphylaxis, while a history of anxiety could be linked to severe neurological AEs. These vaccine recipients require further evaluation and monitoring.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Immunology

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

John Frater et al.

Summary: The study demonstrates that the ChAdOx1 nCoV-19 vaccine is safe and immunogenic in people with HIV, with no serious adverse events reported. Local and systemic reactions were similar to those in HIV-negative participants, and antibody and cellular immune responses in HIV-infected individuals showed similar levels to those in uninfected individuals.

LANCET HIV (2021)

Add to Collection

Article Immunology

Randomized, Double-Blinded, Placebo-Controlled Phase 2 Trial of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in Healthy Adults

Yanchun Che et al.

Summary: This study evaluated an inactivated SARS-CoV-2 vaccine for immunogenicity and safety in adults aged 18-59 years. The results showed that vaccinated adults developed neutralizing antibodies as well as anti-S/N antibodies with a low rate of adverse reactions.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Medicine, General & Internal

Early Safety Monitoring of COVID-19 Vaccines in Healthcare Workers

Joon Young Song et al.

Summary: Hospital-based surveillance found that healthcare workers who received the adenovirus-vectored COVID-19 vaccine experienced higher rates of systemic adverse events compared to mRNA vaccine recipients. Common adverse events among adenovirus-vectored vaccine recipients included fatigue, myalgia, headache, and fever, with most symptoms resolving within 2 days. Both COVID-19 vaccines were generally safe with few serious adverse events reported.

JOURNAL OF KOREAN MEDICAL SCIENCE (2021)

Add to Collection

Article Medicine, General & Internal

Association between previous infection with SARS CoV-2 and the risk of self-reported symptoms after mRNA BNT162b2 vaccination: Data from 3,078 health care workers

Antonella d'Arminio Monforte et al.

Summary: The study found that healthcare workers with a history of COVID-19 are more likely to experience severe and moderate systemic symptoms after vaccination, but no severe adverse events were reported.

ECLINICALMEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials

Hong-Xing Pan et al.

Summary: This study reported the immunogenicity and safety of an inactivated SARS-CoV-2 vaccine, KCONVAC, in healthy adults. The vaccine demonstrated good tolerability and induced robust immune responses in both phase 1 and phase 2 trials.

CHINESE MEDICAL JOURNAL (2021)

Add to Collection

Article Medicine, General & Internal

Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience

Si Ho Kim et al.

Summary: The study in South Korea on healthcare workers receiving COVID-19 vaccinations showed that more adverse events were reported in ChAdOx1 nCoV-19 recipients compared to BNT162b2 recipients. However, most reported adverse events were mild to moderate in severity, emphasizing the importance of providing sufficient explanation and preparation for expected adverse events to promote widespread vaccination.

JOURNAL OF KOREAN MEDICAL SCIENCE (2021)

Add to Collection

Article Medicine, General & Internal

Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea

Seongman Bae et al.

Summary: A prospective survey conducted in South Korea on healthcare workers who received the first dose of two COVID-19 vaccines showed a higher rate of adverse reactions in the ChAdOx1 group compared to the BNT162b2 group. Females and younger age groups were more likely to experience vaccine-associated adverse reactions.

JOURNAL OF KOREAN MEDICAL SCIENCE (2021)

Add to Collection

Article Medicine, General & Internal

Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial

Pablo Tebas et al.

Summary: The study found that the INO-4800 vaccine performed well in inducing immune responses and had good safety, with no serious adverse events reported. Participants exhibited both cellular and humoral immune responses to the vaccine, indicating its effectiveness in eliciting immunity.

ECLINICALMEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

A Novel Coronavirus from Patients with Pneumonia in China, 2019

Na Zhu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Feng-Cai Zhu et al.

LANCET (2020)

Add to Collection

Article Medicine, General & Internal

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes Interim Analysis of 2 Randomized Clinical Trials

Shengli Xia et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Medicine, General & Internal

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Feng-Cai Zhu et al.

LANCET (2020)

Add to Collection

Article Medicine, General & Internal

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Pedro M. Folegatti et al.

LANCET (2020)

Add to Collection

Article Medicine, General & Internal

An mRNA Vaccine against SARS-CoV-2-Preliminary Report

L. A. Jackson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Public, Environmental & Occupational Health

Assessing the Safety of COVID-19 Vaccines: A Primer

Helen Petousis-Harris

DRUG SAFETY (2020)

Add to Collection

Editorial Material Medicine, General & Internal

Postapproval Vaccine Safety Surveillance for COVID-19 Vaccines in the US

Grace M. Lee et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Medicine, General & Internal

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Denis Y. Logunov et al.

LANCET (2020)

Add to Collection

Review Multidisciplinary Sciences

SARS-CoV-2 vaccines in development

Florian Krammer

NATURE (2020)

Add to Collection

Article Medicine, General & Internal

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

E. J. Anderson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Cheryl Keech et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Maheshi N. Ramasamy et al.

LANCET (2020)

Add to Collection

Review Allergy

Vaccine-associated hypersensitivity

Michael M. McNeil et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2018)

Add to Collection

Article Health Care Sciences & Services

The GRADE Working Group clarifies the construct of certainty of evidence

Monica Hultcrantz et al.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

Julian P. T. Higgins et al.

BMJ-BRITISH MEDICAL JOURNAL (2011)

Add to Collection

Editorial Material Medicine, General & Internal

GRADE:: an emerging consensus on rating quality of evidence and strength of recommendations

Gordon H. Guyatt et al.

BRITISH MEDICAL JOURNAL (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.